Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes

Diabetes Care. 2022 Feb 1;45(2):e32-e33. doi: 10.2337/dc21-1800.

Authors

Hui Shao¹, Piaopiao Li¹, Jingchuan Guo¹, Vivian Fonseca², Lizheng Shi³, Ping Zhang⁴

Affiliations

¹ Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL.
² Department of Medicine and Pharmacology, School of Medicine, Tulane University, New Orleans, LA.
³ Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA.
⁴ Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA.

PMID: 35020817
DOI: 10.2337/dc21-1800

No abstract available

Publication types

Letter

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptide-1 Receptor / agonists
Humans
Hypoglycemic Agents / therapeutic use
Socioeconomic Factors
Sodium-Glucose Transporter 2 Inhibitors* / pharmacology
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors